期刊
CLINICAL IMMUNOLOGY
卷 140, 期 2, 页码 196-207出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2011.03.016
关键词
NKT cells; Dendritic cells; Human; Cytokines; Glycolipids
类别
资金
- Science Foundation Ireland
- Irish Health Research Board
- Irish Research Council for Science Engineering and Technology
- [R01 DK066917]
- [R21 CA143748]
Activation of CD1d-restricted invariant NKT (iNKT) cells with the glycolipid alpha-galactosylceramide (alpha-GalCer) confers protection against disease in murine models, however, clinical trials in humans have had limited impact. We synthesized a novel thioglycoside analogue of alpha-GalCer, denoted alpha-S-GalCer, and tested its efficacy for stimulating human iNKT cells in vitro. alpha-S-GalCer stimulated cytokine release by iNKT cells in a CD1d-dependent manner and primed CD1d(+) target cells for lysis. alpha-S-GalCer-stimulated iNKT cells induced maturation of monocyte-derived dendritic cells into antigen-presenting cells that released IL-12 and small amounts of IL-10. The nature and potency of alpha-S-GalCer and alpha-GalCer in human iNKT cell activation were similar. However, in contrast to alpha-GalCer, alpha-S-GalCer did not activate murine iNKT cells in vivo. Because of its enhanced stability in biological systems, alpha-S-GalCer may be superior to alpha-GalCer as a parent compound for developing adjuvant therapies for humans. (C) 2011 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据